Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TL1A


Brief Information

Name:Tumor necrosis factor superfamily member 15
Target Synonym:VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP142-Cell-based assay

Expression analysis of human TL1A on HEK293/Human TL1A Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human TL1A Stable Cell Line or negative control cell using anti-human TL1A Antibody followed by staining with PE anti-human IgG Fc Antibody.


Human TL1A Protein (E120A, E122A, M217A), His Tag (Cat. No. TLA-H5248) immobilized on CM5 Chip can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with an affinity constant of 2.36 nM as determined in a SPR assay (Biacore 8K) (QC tested).


Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) immobilized on CM5 Chip can bind Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) with an affinity constant of 97.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name



TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tulisokibart PRA-023; MK-7240; PRA023 Phase 3 Clinical Prometheus Biosciences Inc, Merck Sharp & Dohme LLC Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Colitis, Ulcerative; Scleroderma, Diffuse; Crohn Disease Details
RVT-3101 PF-06480605; PF 6480605; RVT-3101 Phase 2 Clinical Pfizer Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
TEV-48574 TEV-48574 Phase 2 Clinical Teva Pharmaceutical Industries Ltd Colitis, Ulcerative; Asthma; Crohn Disease Details
Next-generation anti-TL1A antibody(Telavant) Phase 1 Clinical Telavant Inc Fibrosis; Inflammation Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message